Back

Modelling treatment effects for gonorrhoea

Jayasundara, P.; Regan, D. G.; Kuchel, P.; Wood, J. G.

2023-07-03 pharmacology and therapeutics
10.1101/2023.07.03.23292181
Show abstract

Neisseria gonorrhoeae (NG) bacteria have evolved resistance to many of the antibiotics that have been used successfully to treat gonorrhoea infection. To gain a better understanding of potential treatment options for gonorrhoea, we extend a previously developed within-host mathematical model to integrate treatment dynamics by accounting for key pharmacokinetic (PK) and pharmacodynamic (PD) features. This extended model was used to investigate different treatment regimens for two potential treatment options, namely, monotreatment with gepotidacin, and dual treatment with gentamicin and azithromycin. The simulated treatment success rates aligned well with the, albeit limited, clinical trial data that are available. The simulation results indicated that antibiotic treatment failure is associated with failure to successfully clear intracellular NG (NG residing within epithelial cells and neutrophils) and that extracellular PK indices alone cannot differentiate between treatment success or failure. We found that the index defined by the ratio of area under the curve to minimum inhibitory concentration (AUC/MIC) index > 150h, evaluated using intracellular gepotidacin concentration, successfully distinguished between treatment success and failure. For the dual treatment regimen, AUC/MIC index > 140h evaluated using the simulated single drug concentration, representing the combined effect of gentamicin and azithromycin with the Loewe additivity concept, successfully differentiated between treatment success and failure. However, we found this PK threshold associated with dual treatment to be less informative than in the gepotidacin monotreatment case as a majority of samples below this threshold still resulted in infection clearance. Although previous experimental results on the killing of intracellular NG are scarce, our findings draw attention to the importance of further experiments on antibiotic killing of intracellular NG. This will be useful for testing putative new anti-gonorrhoea antibiotics. Author SummaryGonorrhoea is a sexually transmitted infection caused by bacteria of the species Neisseria gonorrhoeae (NG). Although gonorrhoea can be easily treated using antibiotics, due to the propensity of NG to acquire resistance to antimicrobials, available treatment options have greatly diminished and most of the antibiotics used to treat infection in the past are now removed from treatment recommendations. As clinical trials have limitations in terms of expense, duration and ethical constraints they are not ideal for optimising doses, regimens and drug combinations. In this case, simulations through within-host mathematical models are useful in determining the effective dosing regimens and to explore intracellular treatment effects for which there is little experimental evidence. Our simulations identified the importance of treating intracellular NG (NG residing within neutrophils and epithelial cells) and the importance of considering intracellular pharmacokinetic indices when differentiating treatment success and failure. With the use of this model, we can simulate a range of different treatment regimens and drug combinations to assess their effectiveness at various values of the minimum inhibitory concentration which can potentially be used to guide future clinical trial design.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Scientific Reports
based on 701 papers
Top 3%
16.1%
2
PLOS ONE
based on 1737 papers
Top 35%
13.6%
3
Clinical Pharmacology & Therapeutics
based on 19 papers
Top 0.4%
7.9%
4
Antimicrobial Agents and Chemotherapy
based on 17 papers
Top 0.1%
6.7%
5
eLife
based on 262 papers
Top 4%
4.7%
6
Frontiers in Pharmacology
based on 27 papers
Top 1%
2.9%
50% of probability mass above
7
Journal of Antimicrobial Chemotherapy
based on 19 papers
Top 0.3%
2.9%
8
PLOS Biology
based on 14 papers
Top 0.1%
2.6%
9
Nature Communications
based on 483 papers
Top 26%
2.4%
10
Clinical Infectious Diseases
based on 219 papers
Top 11%
2.4%
11
F1000Research
based on 28 papers
Top 0.9%
2.4%
12
British Journal of Clinical Pharmacology
based on 21 papers
Top 1%
2.4%
13
Briefings in Bioinformatics
based on 11 papers
Top 0.2%
1.8%
14
Frontiers in Medicine
based on 99 papers
Top 9%
1.8%
15
Emerging Microbes & Infections
based on 20 papers
Top 0.5%
1.6%
16
Clinical and Translational Science
based on 14 papers
Top 0.9%
1.6%
17
PLOS Computational Biology
based on 141 papers
Top 7%
1.4%
18
PLOS Neglected Tropical Diseases
based on 166 papers
Top 8%
1.4%
19
PeerJ
based on 46 papers
Top 6%
1.4%
20
The Journal of Infectious Diseases
based on 137 papers
Top 7%
1.4%
21
Computational and Structural Biotechnology Journal
based on 14 papers
Top 1%
1.4%
22
Royal Society Open Science
based on 49 papers
Top 4%
1.3%
23
Heliyon
based on 57 papers
Top 10%
0.8%
24
Epidemics
based on 96 papers
Top 7%
0.8%
25
PLOS Digital Health
based on 88 papers
Top 11%
0.8%
26
Microbiology Spectrum
based on 86 papers
Top 3%
0.8%
27
Journal of Allergy and Clinical Immunology
based on 15 papers
Top 2%
0.8%
28
Pathogens
based on 16 papers
Top 0.7%
0.7%
29
JCI Insight
based on 63 papers
Top 6%
0.7%
30
JMIRx Med
based on 29 papers
Top 6%
0.7%